和黄医药“断奶”后压力陡增,呋喹替尼美国市场依然给力

健识局
Aug 08

在剥离了中药资产之后,和黄医药显然有点不适应。8月7日,和黄医药披露了公司的中期业绩:今年上半年,公司收入总额2.78亿美元,同比减少9.16%,不过好在净利润呈出了百倍增长,达4.55亿美元。据悉,净利润大增的原因就是上海和黄药业50%股权出售的一次性收入,达到4.77亿美元。不过财报显示,和黄医药的核心增长产品不再强劲,核心肿瘤、免疫产品,综合收入同比减少了15%。和黄医药提到:在售产品的竞争...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10